Spruce Biosciences, Inc. (SPRB)

Market Cap	22.58M
Revenue (ttm)	9.57M
Net Income (ttm)	-43.11M
Shares Out	41.30M
EPS (ttm)	-1.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	456,500
Open	0.530
Previous Close	0.517
Day's Range	0.512 - 0.566
52-Week Range	0.411 - 5.950
Beta	2.41
Analysts	Hold
Price Target	2.50 (+357.29%)
Earnings Date	Nov 11, 2024

About SPRB

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric clas...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 9, 2020
• Employees: 29
• Stock Exchange: NASDAQ
• Ticker Symbol: SPRB
• Website: https://www.sprucebiosciences.com

Analyst Forecast

According to 7 analysts, the average rating for SPRB stock is "Hold." The 12-month stock price forecast is $2.5, which is an increase of 357.29% from the latest price.

Price Target

$2.5

(357.29% upside)

Analyst Consensus: Hold